Skip to content

Pembrolizumab plus Axitinib

Pembrolizumab plus Axitinib represent a powerful combination therapy used in the treatment of certain types of cancer. Both medications target different aspects of cancer progression and immune system regulation, offering a comprehensive approach to combating cancer cells and enhancing the body’s natural defenses.

Pembrolizumab, a monoclonal antibody, functions by targeting the PD-1 receptor found on immune cells called T cells. This receptor is often exploited by cancer cells to evade immune system detection. By blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2, Pembrolizumab enables T cells to recognize and attack cancer cells effectively. This mechanism, known as immune checkpoint inhibition, helps unleash the immune system’s potential to fight against cancer.

On the other hand, Axitinib is a tyrosine kinase inhibitor that primarily targets vascular endothelial growth factor (VEGF) receptors. These receptors play a crucial role in tumor angiogenesis, the process by which tumors develop blood vessels to sustain their growth. By inhibiting VEGF signaling pathways, Axitinib helps starve tumors of their blood supply, thereby impeding their ability to grow and spread.

When used together, Pembrolizumab and Axitinib create a synergistic effect that can significantly improve treatment outcomes for patients with specific types of cancer, such as advanced sarcomas. This combination is used to treat Alveolar Soft Part Sarcoma